Aslan's lat­est can­cer fo­cus al­so flops, leav­ing just two ma­jor pro­grams for the trou­bled biotech

Aslan $ASLN has stum­bled back in­to the fail­ure pit.

When their lead drug failed to treat gas­tric can­cer, Aslan Phar­ma­ceu­ti­cals an­nounced they were go­ing to fo­cus on an­oth­er type: bil­iary tract can­cer (BTC). When the gas­tric fail­ure forced them to cut 30% of their staff, they again em­pha­sized the new tar­get as one of three re­main­ing pro­grams.

But Aslan’s BTC tri­al has now failed on both pri­ma­ry end­points. The re­sults showed an im­proved re­sponse rate for Aslan’s var­l­i­tinib over the con­trol arm, but not sig­nif­i­cant­ly.  The drug arm had a pro­gres­sion-free sur­vival rate of 2.83 months com­pared to 2.79 in the con­trol arm — ba­si­cal­ly a one-day dif­fer­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.